

CSABA BÖDÖR



Semmelweis University
Faculty of Medicine
Department of Pathology and
Experimental Cancer Research

Address: Üllői út 26., H-1085 Budapest, Hungary

RESEARCH AREA

Our research focuses on better understanding of the genomic background of the malignant diseases of the hematopoietic system, i. e. leukemias and lymphomas with a special focus on identification of biomarkers and development of technologies supporting a more precise diagnosis, risk stratification and application of targeted therapies in this disease group.

TECHNIQUES AVAILABLE IN THE LAB

State of the art molecular genetic technologies. Nucleic acid extraction, polymerase chain reaction, next-generation sequencing, gene expression analyses, genomic databases.

SELECTED PUBLICATIONS

Bödör, C., Kotmayer, L., László, T., Takács, F., Barna, G., Kiss, R., Sebestyén, E., Nagy, T., Hegyi, L.L., Mikala, G., Fekete, S., Farkas, P., Balogh, A., Masszi, T., Demeter, J., Weisinger, J., Alizadeh, H., Kajtár, B., Kohl, Z., Szász, R., Gergely, L., Gurbity Pálfi, T., Sulák, A., Kollár, B., Egyed, M., Plander, M., Rejtő, L., Szerafin, L., Ilonczai, P., Tamáska, P., Pettendi, P., Lévai, D., Schneider, T., Sebestyén, A., Csermely, P., Matolcsy, A., Mátrai, Z., Alpár, D. (2021) Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy. **British Journal of Haematology** **194**: 355-364.

Nagy, Á., Báta, B., Balogh, A., Illés, S., Mikala, G., Nagy, N., Kiss, L., Kotmayer, L., Matolcsy, A., Alpár, D., Masszi, T., Masszi, A., **Bödör, C.** (2020) Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma. **Genes** **11**: 785.

Rendeiro, AF., Krausgruber, T., Fortelny, N., Zhao, F., Penz, T., Farlik, M., Schuster, L.C., Nemc, A., Tasnády, S., Réti, M., Mátrai, Z., Alpár, D., **Bödör, C.**, Schmidl, C., Bock, C. (2020) Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL. **Nature Communications** **11**: 577.

Gángó, A., Alpár, D., Galik, B., Marosvári, D., Kiss, R., Fésüs, V., Aczél, D., Eyüpoglu, E., Nagy, N., Nagy, Á., Krizsán, S., Reiniger, L., Farkas, P., Kozma, A., Ádám, E., Tasnády, S., Réti, M., Matolcsy, A., Gyenesei, A., Mátrai, Z., **Bödör, C.** (2019) Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib. **International Journal of Cancer** **146**: 85-93.

Kiss, R., Alpár, D., Gángó, A., Nagy, N., Eyüpoglu, E., Aczél, D., Matolcsy, A., Csomor, J., Mátrai, Z., **Bödör, C.** (2018) Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia. **Haematologica** **104**: 38-41.